ArticleBiotechnology letters2026
Intranasal immunization in mice with spore-associated serine-aspartate repeat-containing protein D from Staphylococcus aureus secreted in Bacillus subtilis.
Article in Biotechnology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Staphylococcus aureus is a major human pathogen causing diseases ranging from mild skin infections to life-threatening conditions due to its diverse virulence factors. The emergence of antibiotic-resistant strains underscores the urgent need for an effective vaccine, though none has yet achieved clinical success. The nasal mucosa serves as a natural reservoir in about 30% of individuals and represents a key source of subsequent infections, particularly in immunocompromised patients. Among its virulence factors, SdrD, a surface-anchored MSCRAMM adhesin associated with methicillin-resistant strains (MRSA), promotes adherence to squamous epithelial cells by binding to desmoglein 1, facilitating epithelial attachment, evasion of mucociliary clearance, and subsequent invasion. Bacillus subtilis, an endotoxin-free organism recognized for its safety, has been extensively developed as a platform for secreted recombinant protein production. This study aimed to utilize the host strain B. subtilis to express and secrete recombinant SdrD antigen, using the control of a strong IPTG-inducible Pgrac212 promoter in a pHT expression vector for B. subtilis. Following IPTG induction, extracellular SdrD was analyzed by SDS-PAGE and confirmed by Western blotting using anti-SdrD polyclonal antibodies. The intranasal administration of concentrated secretions, combined with B. subtilis spores as adjuvants, to mice elicited significant antigen-specific IgA and IgG responses, providing both mucosal and systemic immunity. The co-administration with spores enhanced both the magnitude and persistence of antibody responses compared to antigen alone. These findings demonstrate that B. subtilis can serve as an effective platform for recombinant protein secretion and mucosal antigen delivery, supporting its application in vaccine development against S. aureus infection via mucosal route.
Indexed as
Identifiers
42696091What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.